MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.

EP: 1.NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP: 2.NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

EP: 3.Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

Now Viewing

EP: 4.MIRASOL trial and DESTINY-PanTumor02 Trial Overview

EP: 5.Tailored Therapy: Decision Making for Ovarian Cancer Treatment

EP: 6.Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

EP: 7.Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!